“Tardive dyskinesia can significantly impact many aspects of patients’ lives, including daily activities, work or school attendance and social interactions,” said Eiry W. Roberts, M.D., Chief Medical ...
SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PRO TM open-label study demonstrating robust and sustained ...
SAN DIEGO, March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced the presentation of new data from a real-world study showing that all patients with tardive ...
Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained ...
"These findings provide critical insights into the real-world use of VMAT2 inhibitors in treating tardive dyskinesia," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results